Tumor microenvironment evaluation to predict pembrolizumab benefit of metastatic gastric cancer: Results from phase II clinical trial.

Dongqiang Zeng,Wangjun Liao,Min Shi,Rui Zhou,Na Huang,Yunfang Yu,Wenying Peng,Jiani Wu,Zilan Ye

Tumor microenvironment evaluation to predict pembrolizumab benefit of metastatic gastric cancer: Results from phase II clinical trial.

2020

Dongqiang Zeng
Wangjun Liao
Min Shi
Rui Zhou
Na Huang
Yunfang Yu
Wenying Peng
Jiani Wu
Zilan Ye

425Background: Clinical studies support the efficacy of immune checkpoint blockades (ICBs) in a subset of patients with metastatic gastric cancer (mGC). With the aim of identifying determinants of ...

Keywords:

Tumor microenvironment
Pembrolizumab
Internal medicine
Medicine
Clinical trial
Oncology
Metastatic gastric cancer
Pathology
Immune checkpoint

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations